3RI5
IVM: (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17 -oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacy clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside
IVM is a Ligand Of Interest in 3RI5 designated by the RCSB
| Best-fitted instance in this entry | |
| Other instances in this entry |
| Best-fitted instance in this entry | |
| Best-fitted PDB instances with different target (top 5) |
| Identifier | Ranking for goodness of fit | Ranking for geometry | Real space R factor | Real space correlation coefficient | RMSZ-bond-length | RMSZ-bond-angle | Outliers of bond length | Outliers of bond angle | Atomic clashes | Stereochemical errors | Model completeness | Average occupancy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3RI5_IVM_B_349 | 33% | 38% | 0.231 | 0.913 | 0.79 | 1.62 | 1 | 17 | 1 | 0 | 100% | 1 |
| 3RI5_IVM_A_349 | 29% | 38% | 0.26 | 0.921 | 0.79 | 1.62 | 1 | 17 | 5 | 0 | 100% | 1 |
| 3RI5_IVM_D_349 | 21% | 37% | 0.28 | 0.892 | 0.8 | 1.63 | 1 | 16 | 2 | 0 | 100% | 1 |
| 3RI5_IVM_E_349 | 17% | 37% | 0.323 | 0.908 | 0.81 | 1.64 | 1 | 18 | 5 | 0 | 100% | 1 |
| 3RI5_IVM_C_350 | 17% | 37% | 0.323 | 0.901 | 0.82 | 1.61 | 1 | 17 | 4 | 0 | 100% | 1 |
| 4WVD_IVM_A_505 | 50% | 4% | 0.186 | 0.938 | 3.38 | 2.16 | 27 | 32 | 6 | 0 | 100% | 1 |
| 5VDI_IVM_C_403 | 42% | 16% | 0.205 | 0.925 | 1.93 | 1.73 | 11 | 19 | 0 | 0 | 100% | 1 |
| 5VDH_IVM_A_403 | 35% | 24% | 0.223 | 0.913 | 1.86 | 1.28 | 8 | 9 | 3 | 0 | 100% | 1 |
| 3RIF_IVM_D_402 | 31% | 37% | 0.232 | 0.903 | 0.8 | 1.64 | 1 | 16 | 2 | 0 | 100% | 1 |
| 3RIA_IVM_A_348 | 23% | 37% | 0.281 | 0.906 | 0.8 | 1.63 | 1 | 15 | 1 | 0 | 100% | 1 |
